BIA response to the Department of Health and Social Care's consultation on proposed changes to the statutory scheme to control costs of branded health service medicines

The BIA has responded to the Department of Health and Social Care's consultation on proposed changes to the statutory scheme to control costs of branded health service medicines.
 
In our submission, we ask the government to consider the combined impact of the proposals and broader developments affecting UK life sciences, including the uncertainty caused by Brexit. We highlight the importance of an internationally-competitive industrial environment for bioscience companies as the UK leaves the EU and we argue that allowable growth in medicine spend should reflect the 5-year funding settlement for the NHS.